Benign Prostatic Hyperplasia
- Benign prostatic hyperplasia (BPH) is overgrowth of the central gland — specifically the transition zone, the doughnut of tissue hugging the urethra.
- It's benign. The "problem" is plumbing: an enlarging gland squeezes the urethra and makes peeing a chore.
- On imaging the giveaways are an enlarged prostate with rounded, encapsulated, often heterogeneous nodules in the transition zone, frequently bulging up into the bladder.
- Volume is the number everyone wants: ellipsoid formula, three diameters × 0.52, measured on T2-weighted MRI or ultrasound.
- The whole reason a radiologist sweats over BPH is that it can mimic — and hide — prostate cancer. On PI-RADS v2.1, T2 is the dominant sequence in the transition zone, and a T2 score 2 nodule only becomes a category 3 if DWI is ≥4.
Imagine a garden hose running through the middle of a slowly inflating water balloon. The balloon doesn't hurt the hose, exactly — it just hugs it tighter and tighter until the stream out the end goes from "firehose" to "sad dribble." That balloon is the prostate. The hose is the urethra. That, in one slightly damp metaphor, is benign prostatic hyperplasia.
What's actually growing
The prostate isn't one uniform blob. It has zones, and BPH is picky about which one it bothers. It targets the transition zone — the ring of tissue that wraps directly around the urethra, like the dough around the hole of a doughnut. (Hold onto the doughnut. We'll need it later.)
As men age, this transition zone tends to enlarge, forming nodules. "Hyperplasia" just means more cells than there used to be — not abnormal cells, just an enthusiastic crowd of normal ones. Crucially, this is not cancer and doesn't turn into cancer. It's the architectural equivalent of your closet slowly filling up: nothing in there is dangerous, there's just too much of it, and now the door won't shut.
The peripheral zone — the back outer rim of the gland — is where most prostate cancer lives. BPH is a transition-zone story. Keeping those two neighborhoods straight is half the battle in prostate imaging.
Why anyone cares: it's a plumbing problem
The symptoms are all about flow. As the transition zone swells, it pinches the urethra and pushes up against the bladder neck. The result is the classic constellation of lower urinary tract symptoms — weak stream, hesitancy ("ready when you are, bladder"), incomplete emptying, and getting up repeatedly at night to negotiate with a reluctant faucet.
The bladder, being a muscle, fights back by working harder, and over time its wall thickens and can develop little out-pouchings (diverticula). If the obstruction gets bad enough, urine backs up all the way to the kidneys — that's the genuinely worrying end of the spectrum, and the reason BPH isn't purely a quality-of-life nuisance.
Findings by modality
Ultrasound
BPH is often first noticed incidentally, on a scan ordered for something else entirely. On transabdominal ultrasound the gland is enlarged and indents the bladder base like a thumb pressed into a balloon; a median-lobe nodule can protrude into the bladder lumen and pass for a bladder mass. Look at the bladder itself: a thickened, trabeculated wall and diverticula are the muscular bladder's fingerprints of chronic straining. The post-void residual (PVR) is measured here — three orthogonal bladder diameters after the patient voids — and a large residual means the obstruction is winning. There is no widely accepted cutoff for "large," so state the volume and let the urologist judge it.
Transrectal ultrasound (TRUS) shows the transition zone as heterogeneous, nodular, and often calcified along the surgical capsule, the compressed rim between transition and peripheral zones. TRUS gives the most accurate volume, using the same ellipsoid formula below.
CT
CT shows an enlarged gland, often with coarse calcifications, protruding into the bladder base. It can show the downstream consequences — thick bladder wall, diverticula, hydroureteronephrosis — but it cannot separate BPH from cancer inside the gland. A mass at the bladder base on CT that is in continuity with the prostate is a median lobe until proven otherwise.
MRI
MRI is where BPH has personality. The transition zone fills with well-defined, rounded, encapsulated nodules of mixed T2 signal — a look people describe as "organized chaos." Glandular nodules are bright on T2 (they contain fluid-filled acini); stromal nodules are dark (they are mostly smooth muscle and fibrous tissue). Cystic degeneration is common. The peripheral zone gets squashed into a thin, bright posterior rim, and the whole gland may bulge up into the bladder.
On PI-RADS v2.1 the transition zone is scored on T2, and the entire skill is margin-reading: a round nodule with a complete dark capsule is the typical benign nodule and scores low; an ill-defined, lenticular, homogeneous dark lesion that erases the boundaries of its neighbors is the one that scores high. Stromal nodules can be dark on the ADC map, which is why DWI alone can't be trusted here; by rule, a T2 score 2 lesion in the transition zone becomes category 3 only if its DWI score is ≥4, and a T2 score 3 becomes a 4 only if DWI is 5.
The numbers
| What | Threshold / value | Why it matters |
|---|---|---|
| Prostate volume (ellipsoid formula) | Maximum anteroposterior × longitudinal (mid-sagittal T2W) × transverse (axial T2W) diameters × 0.52 | Sizes the gland, feeds PSA density, and steers the choice of medical versus procedural treatment |
| Dominant PI-RADS v2.1 sequence in the transition zone | T2-weighted imaging | BPH lives here, so shape and margins on T2 decide the score |
| Transition-zone upgrade rules (PI-RADS v2.1) | T2 score 2 becomes category 3 if DWI is ≥4; T2 score 3 becomes category 4 if DWI is 5, otherwise stays 3 | The only way a nodule that looks benign on T2 climbs the ladder |
| High b-value DWI needed for that DWI score | ≥1400 s/mm², acquired or calculated | Without it, the DWI rescue rule can't be applied honestly |
| A normal or "enlarged" volume cutoff | Not stated here | There is no accepted volume norm, so report the number rather than a label |
| Post-void residual cutoff | Not stated here | Same reason; give the measured volume |
The formula is the takeaway: three diameters × 0.52. Take the maximum anteroposterior diameter, the longitudinal diameter on the mid-sagittal T2 image, and the transverse diameter on the axial T2 image. Everyone measures it, so measure it the same way every time.
How good is the test
BPH is a clinical diagnosis made on symptoms and examination; imaging measures the gland and its consequences rather than diagnosing the condition, and there is no robust sensitivity or specificity figure for imaging in BPH itself. Where numbers do exist is on the question BPH hides: a meta-analysis of 21 studies and 3857 patients found PI-RADS version 2 had a pooled sensitivity of 89% and a pooled specificity of 73% for prostate cancer. A busy, nodular, diffusion-restricting transition zone that turns out to be benign is one classic way to lose specificity.
PI-RADS v2.1 in the transition zone, abbreviated
Version: PI-RADS v2.1. The full lesion-scoring logic is on prostate MRI.
| Category | Likelihood of clinically significant cancer | Transition-zone route |
|---|---|---|
| 1 | Very low | T2 score 1 |
| 2 | Low | T2 score 2 (typical encapsulated nodule) with DWI below 4 |
| 3 | Intermediate (equivocal) | T2 score 3, or T2 score 2 with DWI ≥4 |
| 4 | High | T2 score 4 (lesion <1.5 cm in greatest dimension), or T2 score 3 with DWI 5 |
| 5 | Very high | T2 score 5: ≥1.5 cm in greatest dimension, or definite extraprostatic extension or invasive behavior |
The trap: BPH versus cancer
Here's where the doughnut comes back to bite us. BPH nodules can be heterogeneous, can restrict diffusion, and can look angry enough to make you reach for the biopsy gun. But most of that drama lives in the transition zone, where BPH belongs — whereas the lesions you truly fear tend to sit in the peripheral zone.
| Mimic | Looks similar because | Tell them apart by |
|---|---|---|
| Transition-zone cancer | Dark on T2 in the same neighborhood | Lenticular, ill-defined, homogeneous, erases margins ("erased charcoal"); benign nodules are round with a complete capsule |
| Stromal BPH nodule mimicking cancer | Dark on T2 and can be dark on ADC | Encapsulated and round; apply the rule that T2 score 2 only becomes 3 if DWI is ≥4 |
| Prostatitis | Restricted diffusion and low T2 | Diffuse or band-like, often in the peripheral zone, diffuse enhancement, clinical symptoms |
| Median lobe versus bladder tumor | Both are a mass at the bladder base | The median lobe is contiguous with the transition zone and shares its nodular signal; a bladder tumor arises from the wall |
| Prostatic abscess | Heterogeneous enlarged gland | Rim-enhancing fluid collection with central restricted diffusion; fever |
| Extruded BPH nodule in the peripheral zone | Dark focus where cancers live | Encapsulated and continuous with the transition zone; no smearing |
A rounded, well-encapsulated transition-zone nodule is the friendly face of BPH. A lesion that's ill-defined, lentiform (lens-shaped), erases the normal boundary, or smudges into the capsule is the one that earns a worried second look. Don't let a busy, nodular transition zone lull you into ignoring the peripheral zone — and don't call every bright BPH nodule a tumor.
This is exactly the tension the scoring systems were built to manage, and it's why transition-zone lesions are judged on their T2 shape on dedicated prostate MRI — covered over in Prostate Cancer Staging (mpMRI).
Reporting
What the urologist needs:
- Volume by the ellipsoid formula (three diameters × 0.52), with the three diameters stated.
- Median lobe protrusion into the bladder: present or absent (it changes the procedure).
- Bladder: wall thickening, trabeculation, diverticula, stones, and the measured post-void residual.
- Upper tracts: hydroureteronephrosis, yes or no.
- On MRI, any transition-zone lesion that is not a typical encapsulated nodule, with its PI-RADS v2.1 category, and a clear statement about the peripheral zone.
How it gets fixed
Most men start with medications that relax the urethra or shrink the gland. When pills aren't enough, urologists offer procedures to physically core out or vaporize the obstructing tissue, and the volume you reported helps choose between them. Interventional radiology has a stake here too: prostate artery embolization starves the gland of blood supply so it shrinks, easing the squeeze without surgery.
If you remember one thing: BPH is a benign overgrowth of the transition zone that strangles the urethra. It won't become cancer — but a crowded, nodular gland is exactly the camouflage cancer loves, so the radiologist's job is to read the plumbing and keep one eye on the peripheral zone.
References
- Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019;76(3):340–351. Used for: the ellipsoid prostate volume formula (AP × longitudinal on mid-sagittal T2W × transverse on axial T2W × 0.52), T2 as the dominant transition-zone sequence, the transition-zone upgrade rules (T2 score 2 to category 3 if DWI ≥4; T2 score 3 to category 4 if DWI 5), the ≥1400 s/mm² high b-value minimum, the PI-RADS v2.1 categories 1–5, and the 1.5 cm and extraprostatic-extension criteria for score 5, in the Key Points, "Findings by modality," "The numbers," "PI-RADS v2.1 in the transition zone, abbreviated," "The trap," and "Reporting."
- Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol 2017;72(2):177–188. Used for: the pooled sensitivity of 89% and pooled specificity of 73% for PI-RADS v2 across 21 studies and 3857 patients in "How good is the test."
Sign in to take the quiz and track your progress